Insulet Corporation’s Q1 2025 Earnings Anticipated with Strong Growth Prospects
Insulet Corporation (PODD) has a market capitalization of $17.2 billion and is recognized for its innovative Omnipod Insulin Management System. This tubeless solution offers a seamless continuous insulin delivery option for individuals with insulin-dependent diabetes. Additionally, Insulet collaborates with pharmaceutical and biotechnology companies to adapt its Omnipod platform for the subcutaneous delivery of various drugs across a range of therapeutic areas.
Upcoming Fiscal Earnings Announcement
The Acton, Massachusetts-based company is set to announce its fiscal Q1 2025 earnings on Thursday, May 8, after the market closes. Analysts predict that PODD will report an adjusted EPS of $0.81, representing nearly an 11% increase from $0.73 in the same quarter last year. Notably, PODD has exceeded Wall Street’s profit forecasts in three out of the last four quarters, although it did miss expectations on one occasion.
Fiscal 2025 Projections and Performance
For fiscal 2025, experts project that Insulet will achieve an adjusted EPS of $4.28, marking a 32.1% increase from $3.24 in fiscal 2024.
Stock Performance Compared to Market
PODD has shown remarkable resilience, with shares soaring 58.8% over the past year. In contrast, the S&P 500 Index ($SPX) only gained 9.4%, while the Health Care Select Sector SPDR Fund (XLV) experienced a 1.3% decline in the same timeframe.
Challenges Despite Strong Earnings
On February 20, Insulet reported adjusted Q4 2024 EPS of $1.15 and revenues of $597.5 million, exceeding expectations. However, PODD’s shares dropped by 1.9% the following day due to concerns about a 17.8% decline in year-over-year adjusted EPS. Furthermore, the company noted a contraction of 258 basis points in the operating margin and a projected 45%-55% decline in Drug Delivery revenues for 2025, which overshadowed the anticipated 17%-21% revenue growth from Omnipod.
Analyst Ratings and Future Outlook
Analysts maintain a bullish consensus on Insulet stock, issuing a “Strong Buy” rating overall. Out of 22 analysts covering the stock, 17 have rated it as “Strong Buy,” with two “Moderate Buys” and three “Holds.” The average analyst price target for PODD stands at $315.29, indicating a potential upside of 20.9% from current price levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
